ViaMune, Inc.

ViaMune is a preclinical-stage company with a mission to enable immunotherapy for patients with advanced cancers.

  • Stage Product In Development
  • Industry Biotechnology
  • Location Athens, GA, US
  • Currency USD
  • Founded June 2011
  • Employees 2
  • Website viamune.com

Company Summary

ViaMune offers a fully synthetic vaccine platform that generates robust immune responses to tumor-specific targets. ViaMune's patented technology provides a unique path to targeting structures found only on tumor cells. ViaMune is seeking financing to complete IND submission, achieve Phase 1 milestones and advance its pipeline. ViaMune is anchored by a leadership team with deep experience in oncology and pharmaceutical development.

Team

  • Alex Harvey

  • Russell Medford
    Chairman of the board

    Managing Partner at Salutramed, Prior: CEO of AtheroGenics (AGIX), Founding Board Director of Inhibitex (INHX)

  • Geert-Jan Boons, PhD
    President and Chief Scientific Officer

    Professor of Chemistry at the University of Georgia: Leader in the study and chemical synthesis of complex, bioactive compounds. Inventor of MTI and ViaTIP (vaccine platform targeting disease-specific glycopeptide structures).

  • Margaret K Offermann
    Chief Medical Officer

    Managing Partner at Salutramed Group, Medical oncologist and tumor biologist; Prior: Professor, Emory University School of Medicine; Deputy National Vice President for Research at the American Cancer Society; Medical Director, Mission Cancer Center; President, FASEB.

Starting a startup?

Join the world's largest startup network for guidance, tools, and fundraising opportunities.

Get Started for Free